Aravive, Inc. ARAV
We take great care to ensure that the data presented and summarized in this overview for Aravive, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARAV
View all-
Acadian Asset Management LLC Boston, MA1.76MShares$00.0% of portfolio
-
Xtx Topco LTD London, X0108KShares$00.0% of portfolio
-
Virtu Financial LLC New York, NY37.6KShares$00.0% of portfolio
-
Act Capital Management, LLC Wayne, PA18.8KShares$00.02% of portfolio
-
Massmutual Trust CO Fsb9.3KShares$00.0% of portfolio
Latest Institutional Activity in ARAV
Top Purchases
Top Sells
About ARAV
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Insider Transactions at ARAV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 24
2022
|
Fredric N Eshelman Executive Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
16,306,120
+38.99%
|
$0
$0.92 P/Share
|
|
Oct 24
2022
|
Peter Tai Ching Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
54,353
+49.54%
|
$0
$0.92 P/Share
|
|
Oct 24
2022
|
Gail Frances Mc Intyre CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
54,353
+45.35%
|
$0
$0.92 P/Share
|
|
Oct 24
2022
|
Rudy Howard Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,870
+50.0%
|
$0
$0.92 P/Share
|
|
Oct 24
2022
|
Eric Zhang Director |
BUY
Grant, award, or other acquisition
|
Direct |
543,537
+27.92%
|
$0
$0.92 P/Share
|
|
Oct 24
2022
|
Amato Giaccia Director |
BUY
Grant, award, or other acquisition
|
Direct |
271,768
+18.3%
|
$0
$0.92 P/Share
|
|
Apr 01
2022
|
Fredric N Eshelman Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,545,455
+33.04%
|
-
|
|
Mar 29
2022
|
Fredric N Eshelman Executive Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
860,216
+15.57%
|
$1,720,432
$2.33 P/Share
|
|
Dec 03
2021
|
Amato Giaccia Director |
SELL
Bona fide gift
|
Direct |
48,366
-4.88%
|
-
|
|
Nov 30
2021
|
Amato Giaccia Director |
SELL
Open market or private sale
|
Direct |
3,245
-0.11%
|
$9,735
$3.22 P/Share
|
|
Nov 30
2021
|
Amato Giaccia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
51,611
+1.69%
|
$0
$0.18 P/Share
|
|
Jun 29
2021
|
Vinay Shah Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.52%
|
$5,000
$5.31 P/Share
|
|
Jun 29
2021
|
Gail Frances Mc Intyre CEO and President |
BUY
Open market or private purchase
|
Direct |
1,000
+8.24%
|
$5,000
$5.34 P/Share
|
|
Mar 19
2021
|
Amato Giaccia Director |
SELL
Bona fide gift
|
Direct |
12,083
-1.27%
|
-
|
|
Mar 19
2021
|
Amato Giaccia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,083
+0.63%
|
$0
$0.06 P/Share
|
|
Feb 12
2021
|
Fredric N Eshelman Executive Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
2,875,000
+43.03%
|
$20,125,000
$7.29 P/Share
|
|
Dec 04
2020
|
Gail Frances Mc Intyre CEO and President |
BUY
Open market or private purchase
|
Direct |
8,000
+44.11%
|
$40,000
$5.77 P/Share
|
|
Dec 04
2020
|
Vinay Shah Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+4.04%
|
$40,000
$5.76 P/Share
|
|
Sep 22
2017
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,650,000
-10.86%
|
$4,950,000
$3.18 P/Share
|
|
Sep 21
2017
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
480,000
-5.8%
|
$1,440,000
$3.65 P/Share
|